Solute carrier family 4 member 4 (SLC4A4) is associated with cell proliferation, migration and immune cell infiltration in colon cancer

Author:

Yu Chengqing1,Li Haoran1,Zhang Chen1,Tang Yuchen1,Huang Yujie1,Lu Haodong1,Jin Kanghui1,Zhou Jian1,Yang Jian1

Affiliation:

1. The First Affiliated Hospital of Soochow University

Abstract

Abstract Background Solute Carrier Family 4 Member 4 (SLC4A4) is a membrane protein-coding gene for a Na+/HCO3 cotransporter and plays a crucial role in regulating pH, bicarbonate secretion and homeostasis. However, the prognostic and immunological role of SLC4A4 in colon cancer remains unknown. Method In this study, expression profiles of SLC4A4 were retrieved from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, to which a variety of bioinformatic analyses were performed. Sangerbox, Xiantao, ESTIMATE and TIMER online tools were used to delve into the relationship between SLC4A4 expression and immune cell infiltration. The role of SLC4A4 in the proliferation and migration of colon cancer cells was verified by CCK8, EdU and wound healing assays. The related molecules and pathways that SLC4A4 may affect were validated by bioinformatic prediction and western blotting analysis. Results The expression levels of SLC4A4 were significantly lower in colon cancer tissues than in normal tissues and its low expression was positively correlated with poor prognosis. TIMER and ESTIMATE showed that SLC4A4 broadly influenced immune cell infiltration. Experiments in vitro demonstrated that SLC4A4 inhibited partial epithelial-mesenchymal transition (EMT) phenotypes. Conclusions To conclude, our study revealed that SLC4A4 is lowly expressed in colon cancer tissues, and SLC4A4 may inhibit the progression of colon cancer via regulating partial EMT phenotypes and immune cell infiltration, which may provide new perspectives for the development of more precise and personalized immune anti-tumor therapies.

Publisher

Research Square Platform LLC

Reference65 articles.

1. Clinical Updates for Colon Cancer Care in 2022;Fabregas JC;Clin Colorectal Cancer,2022

2. Pathophysiology, clinical presentation, and management of colon cancer;Cappell MS;Gastroenterol Clin North Am,2008

3. Hallmarks of cancer: the next generation;Hanahan D;Cell,2011

4. DeBerardinis RJ, Chandel NS. Fundamentals cancer metabolism Sci Adv. 2016;2(5):e1600200.

5. Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression;Li Z;Cell Mol Life Sci,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3